HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

dubermatinib

an AXL inhibitor with antineoplastic activity

Also Known As:

2-((5-chloro-2-(4-((4-methylpiperazin-1-yl)methyl)anilino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; TP-0903; TP0903

Networked: 10 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Whatcott, Clifford J: 2 articles (12/2020 - 01/2020)
2.	Warner, Steven: 2 articles (01/2020 - 04/2016)
3.	Arner, Emily N: 1 article (01/2022)
4.	Brekken, Rolf A: 1 article (01/2022)
5.	Choi, Sangtae: 1 article (01/2022)
6.	Foulks, Jason M: 1 article (01/2022)
7.	Huang, Huocong: 1 article (01/2022)
8.	Kim, Se-Hee: 1 article (01/2022)
9.	Lee, Won-Suk: 1 article (01/2022)
10.	Rizvi, Ali: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2016 - "These studies identify TP-0903 as a new therapeutic for activating RAin vivoand raise the possibility that RA-dependent inhibition of EMT contributes to its prior success in eliminating disseminated cancer cells. " 01/01/2022 - "We demonstrate that TP-0903 as a single agent or in combination with gemcitabine and/or anti-programmed cell death protein 1 (PD1) antibody has anti-metastatic and anti-tumor effects in PDA tumor bearing mice, leading to increased survival. " 01/01/2020 - "Patient-derived organoids (PDO) obtained from tumors with high AXL and JAK1 were sensitive to TP-0903 and ruxolitinib (JAK inhibitor) treatments, supporting the CyTOF findings. "
2.	Respiratory Syncytial Virus Infections 01/01/2023 - "In an animal model of pulmonary RSV infection, treatment with BMS-777607, R428, or TP-0903 ameliorated pulmonary pathology with a significant reduction of RSV titers in the lung tissues and, consequently, decreased the expression of proinflammatory genes. " 01/01/2023 - "Axl inhibition with kinase inhibitors, including BMS-777607, R428, and TP-0903, or Axl ablation resulted in a significant reduction of RSV infection in cell-based assays. "
3.	Colonic Neoplasms (Colon Cancer) 01/01/2022 - "Therefore, we suggest that treatment of bevacizumab and TP-0903 inhibits TGF-β1-induced EMT of colon cancer cells through inactivation of the Smad 2/3 signaling pathway." 01/01/2022 - "Bevacizumab and anexelekto inhibitor, TP-0903 inhibits TGF-β1-induced epithelial-mesenchymal transition of colon cancer cells." 01/01/2022 - "In this study, we investigated whether the anticancer drug bevacizumab and anexelekto inhibitor, TP-0903, regulate EMT of colon cancer cells induced by transforming growth factor-beta 1 (TGF-β1). " 01/01/2022 - "In addition, we elucidated that bevacizumab and TP-0903 inhibited the migration and invasion of TGF-β1-exposed colon cancer cells using scratched wound healing, transwell migration, and Matrigel-coated invasion assays. "
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/21/2022 - "TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion." 12/03/2020 - "TP-0903 is active in models of drug-resistant acute myeloid leukemia."
5.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/2016 - "Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia."

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	N- (4- (2- amino- 3- chloropyridin- 4- yloxy)- 3- fluorophenyl)- 4- ethoxy- 1- (4- fluorophenyl)- 2- oxo- 1,2- dihydropyridine- 3- carboxamide
3.	Transforming Growth Factor beta (TGF-beta)
4.	Bevacizumab (Avastin)
5.	Programmed Cell Death 1 Receptor
6.	Metformin (Glucophage)
7.	Doxorubicin (Adriamycin)
8.	Gemcitabine
9.	Janus Kinase Inhibitors
10.	ibrutinib

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)